Friedelane Triterpenes with Cytotoxic Activity from the Leaves of Maytenus quadrangulata (Celastraceae)

Three new triterpenes, 3,4-seco-3,11β-epoxyfriedel-4(23)-en-3β-ol (1), friedelan- 3α,11β‑diol (2), 7β,26-epoxyfriedelan-3a,7a-diol (3), a mixture of two new triterpenes 3a-hydroxyfriedelan-29-yl palmitate (4) and 3α-hydroxyfriedelan-29-yl stearate (5) and eleven known compounds were obtained from th...

Full description

Saved in:
Bibliographic Details
Published inJournal of the Brazilian Chemical Society Vol. 33; no. 11; pp. 1281 - 1290
Main Authors de Aguilar, Mariana, de Sousa, Grasiely, Evangelista, Fernanda, Sabino, Adriano, Camargo, Karen, Vieira Filho, Sidney, Nunes, Yule, Duarte, Lucienir
Format Journal Article
LanguageEnglish
Published SAO PAULO Soc Brasileira Quimica 01.11.2022
Sociedade Brasileira de Química
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Three new triterpenes, 3,4-seco-3,11β-epoxyfriedel-4(23)-en-3β-ol (1), friedelan- 3α,11β‑diol (2), 7β,26-epoxyfriedelan-3a,7a-diol (3), a mixture of two new triterpenes 3a-hydroxyfriedelan-29-yl palmitate (4) and 3α-hydroxyfriedelan-29-yl stearate (5) and eleven known compounds were obtained from the hexane extract of Maytenus quadrangulata leaves. The structures and the relative stereochemistry of the new triterpenes were established through 1D/2D nuclear magnetic resonance (NMR), high resolution mass spectrometry (HRMS), and Fourier transform infrared (FTIR) spectral data. The hexane extract and isolated compounds were submitted to the cytotoxicity assays against leukemia (THP-1 and K562), ovarian (TOV-21G) and breast cancer (MDA-MB-231) cell lines. Compounds 1, 2 and 11β-hydroxyfriedelan-3-one (15) displayed high cytotoxicity and selectivity against leukemic cells when compared to positive control cytarabine (for THP-1) and imatinib (for K562). Furthermore, compound 2 showed similar cytotoxicity and an enhanced selectivity towards ovarian and breast cells in comparison to positive control etoposide.
ISSN:0103-5053
1678-4790
1678-4790
DOI:10.21577/0103-5053.20220058